May 16, 2016 Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
May 5, 2016 Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results
April 26, 2016 Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May 5, 2016
March 10, 2016 Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results
March 1, 2016 Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
February 17, 2016 Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
